You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

Maximizing the Safety of CAR T-Cell Therapy

  • Authors: Stephanie Jackson, RN, MSN, RN, AOCNS, BMTCN; Leslie Smith, RN, AOCNS, APRN-CNS
  • CE Released: 2/13/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 2/13/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for nurses.

The goal of this activity is to provide education on the prevention and management of adverse events (AEs) associated with chimeric antigen receptor (CAR) T-cell therapies.

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Adverse effects associated with CAR T-cell therapy in lymphoma
  • Preventive measures to take for patients with lymphoma receiving CAR T-cell therapy


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Stephanie Jackson, RN, MSN, AOCNS, BMTCN

    Oncology Clinical Nurse Specialist, UCLA Medical Center, Los Angeles, California

    Disclosures

    Disclosure: Stephanie Jackson, RN, MSN, AOCNS, BMTCN, has disclosed no relevant financial relationships.

    Ms Jackson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Jackson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

  • Leslie Smith, RN, AOCNS, APRN-CNS

    Oncology and Transplant Clinical Nurse Specialist, Germantown, Maryland

    Disclosures

    Disclosure: Leslie Smith, RN, AOCNS, APRN-CNS, has disclosed no relevant financial relationships.

    Ms Smith does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Smith does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Sarah Williams, PhD

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

Maximizing the Safety of CAR T-Cell Therapy

Authors: Stephanie Jackson, RN, MSN, RN, AOCNS, BMTCN; Leslie Smith, RN, AOCNS, APRN-CNSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 2/13/2018

Valid for credit through: 2/13/2019

processing....

Educational Impact Challenge

The goal of this activity is to provide education on the prevention and management of adverse events (AEs) associated with chimeric antigen receptor (CAR) T-cell therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print